Supreme Court Questions High Cancer Drug Markups and Hospital Pharmacy Practices
The Supreme Court of India expressed concern over hospitals charging up to ten times the price of cancer drugs, highlighting a cancer medicine priced at Rs 27,000 while its retailer price is Rs 2,700. The court suggested a uniform 16% margin on all medicines and asked the government to investigate hospitals mandating patients to buy medicines from in-house or designated pharmacies. Following the court's remarks, major hospital stocks, including Apollo and Fortis, declined. The issue raises concerns about patient affordability and hospital pricing practices under the Drugs (Prices Control) Order, 2013.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is neutral (42/100). Lens Score 63/100.
Outlets measured: economictimes, indiatoday, thetribune, businessstandard, moneycontrol, zeenews, freepressjournal, thehindu, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 4 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (28–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 29 Sept, 08:51 am. Other outlets followed.
